Table 1.
Classification of acute myeloid leukemia with recurrent genetic abnormalities
| WHO2016 | WHO2022 | ICC | |||
|---|---|---|---|---|---|
| Classification | Blast (%) | Classification | Blast (%) | Classification | Blast (%) |
| AML with recurrent genetic abnormalities | AML with defining genetic abnormalities | AML with recurrent genetic abnormalities | |||
| APL with PML::RARA | . | APL with PML::RARA fusion | . |
APL with t(15;17)(q24.1;q21.2)/PML::RARA APL with other RARA rearrangement |
≥ 10 |
| AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 | . | AML with RUNX1::RUNX1T1 fusion | . | AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 | ≥ 10 |
|
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11 |
. | AML with CBFB::MYH11 fusion | . |
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11 |
≥ 10 |
| AML with t(9;11)(p21.3;q23.3);KMT2A::MLLT3 | ≥ 20 | AML with KMT2A rearrangement | . |
AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A AML with other KMT2A rearrangement |
≥ 10 |
| AML with t(6;9)(p23;q34.1);DEK::NUP14 | ≥ 20 | AML with DEK::NUP214 fusion | . | AML with t(6;9)(p23;q34.1)/DEK::NUP14 | ≥ 10 |
|
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2::MECOM |
≥ 20 | AML with MECOM rearrangement | . |
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2;MECOM(EVI1) AML with other MECOM rearrangement |
≥ 10 |
| AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 | ≥ 20 | AML with BCR::ABL1 fusion | ≥ 20 | AML with t(9;22)(22)(q34.1;q11.2)/BCR::ABL1 | ≥ 20 |
| AML with t(1;22)(p13.3;q13.1);RBM15::MLK1 | ≥ 20 | AML with RBM15::MRTFA fusion | . | ≥ 10 | |
| AML with mutated NPM1 | . | AML with NPM1 mutation | AML with mutated NPM1 | ≥ 10 | |
| AML with biallelic mutation of CEBPA | . | AML with CEBPA mutation | ≥ 20 | AML with mutated bZIP CEBPA | ≥ 10 |
| (provisional) AML with mutated RUNX1 | ≥ 20 | AML with NUP98 rearrangement | . | AML with TP53 | ≥ 20 |
| AML myeloid leukemia, myelodysplasia-related | ≥ 20 | AML with other rare recurring translocations | ≥ 10 | ||
| AML with other defined genetic alteration | ≥ 20 | AML with t(1;3)(p36.3;q21.3)/PRDM16::RPN1 | |||
| AML with t(3;5)(q25.3)(q25.3;q35.1)/NPM1::MLF1 | |||||
| AML with t(8;16)(p11.2;p13.3)/KAT6A::CREBBP | |||||
| AML with t(1;22)(p13.3;q13.1)/RBM15::MRTF1 | |||||
| AML with t(5;11)(q35.2;p15.4)/NUP98:NSD1 | |||||
| AML with t(11;12)(p15.4;p13.3)/NUP98::KMD5A | |||||
| AML with NUP98 and other partners | |||||
| AML with t(7;12)(q36.3;p13.2)/ETV6::MNX | |||||
| AML with t(10;11)(p12.3);q14.2)/PICALM::MLLT10 | |||||
| AML with t(16;21)(p11.2;q22.2)/FUS::ERG | |||||
| AML with t(16;21)(q24.3;q22.1)/RUNX1::CBFA2T3 | |||||
| AML with inv(16)(p13.3;q24.3)/CBFA2T3::GLIS2 | |||||
Abbreviations: AML Acute myeloid leukemia, APL Acute promyelocytic leukemia